Shionogi & Co., Ltd. (SGIOF)

Market Cap	13.18B
Revenue (ttm)	2.91B
Net Income (ttm)	1.07B
Shares Out	n/a
EPS (ttm)	1.26
PE Ratio	12.29
Forward PE	n/a
Dividend	0.59 (3.92%)
Ex-Dividend Date	Sep 27, 2024

Volume	150
Average Volume	436
Open	15.00
Previous Close	16.23
Day's Range	15.00 - 15.00
52-Week Range	37.02 - 53.50
Beta	0.22
RSI	54.17
Earnings Date	May 12, 2025

About Shionogi &

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1878
• Employees: 4,959
• Stock Exchange: OTCMKTS
• Ticker Symbol: SGIOF

Financial Performance

In 2023, Shionogi &'s revenue was 435.08 billion, an increase of 1.97% compared to the previous year's 426.68 billion. Earnings were 162.03 billion, a decrease of -12.40%.

Financial numbers in JPY